379 results about "Gout" patented technology

The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

Provided herein are methods and compositions and kits related to uricase compositions and / or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.

The invention discloses a preparation method and application of a medicinal and edible composition for reducing uric acid and treating gout, and belongs to the crossing field of medicine and food technologies. The composition is composed of celery seeds, sophora flower buds, chicory, dandelion, mulberry twigs, pawpaw and fresh lalang grass rhizomes, all the components have a synergistic effect, and the effects of inhibiting generation of uric acid, promoting excretion of uric acid, resisting inflammation, diminishing swelling and adjusting body metabolism at multiple target points are achieved. The preparation method comprises the steps of intelligent screening and fine pretreatment of raw materials, a multi-stage targeted extraction process and intelligent concentration and precise forming, and active ingredients can be efficiently extracted and prepared into various dosage forms. According to the composition, in the aspect of precise medical assistance, personalized medication schemes are customized according to different stages of gout, and whole-course digital management is achieved by means of intelligent equipment and a cloud platform; in daily smart health care of families, gout prevention of the families is facilitated through smart home kitchen equipment and a uric acid monitoring set; the method is used for innovative health food development, and provides a new natural, efficient and multifunctional health management approach for gout patients.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1-5. The uric acid reducing effect is verified by adopting an in-vitro XOD inhibition experiment and a cell experiment; furthermore, the uric acid reducing and gout resisting activity of the compound is verified through a hyperuricemia animal model, and a theoretical basis is provided for high-valued utilization of the belly-swelling hippocampus and development of uric acid reducing and gout resisting products.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The present invention provides a method for establishing a hyperuricemia prediction model using a machine learning algorithm, which belongs to the field of health assessment technology. The embodiment of the present invention uses a UKBB cohort based on a large population as training, and uses an internal test set and a dataset of healthy physical examinees from Southern Hospital as an external test set to establish and verify a reliable and practical stacked multimodal machine learning model trained based on genetic and clinical data, which is used to timely identify HUA phenotypes and early predict gout and metabolic-related outcome risks. The model has excellent performance, exceeding each single machine learning model, and shows satisfactory efficacy. The ISHUA marker can quantify gout risk and metabolic-related results at an early stage, can provide active guidance for daily health examinations and the management of risk factors, and provide valuable information support for clinicians to appropriately manage HUA risk factors after routine health screening.

The invention provides a gout diagnosis and recurrence risk prediction method and system based on Raman spectrum and multi-modal machine learning, and the method comprises the steps: generating a Raman spectrum sample data set, and carrying out the preprocessing; performing data dimension reduction and feature extraction on the preprocessed Raman spectrum sample data set to obtain key feature vectors; performing feature screening and enhancement on the key feature vectors before modeling; modeling the data before and after dimension reduction by using a machine learning algorithm to obtain a plurality of machine learning models; and training the multiple machine learning models by using a training set, verifying the models by using a ten-fold cross validation method, selecting the machine learning model with the best discrimination effect as a prediction model, and performing risk prediction of medical history development and gout recurrence. The Raman spectrum and the advanced artificial intelligence technology are integrated, a new prospect is provided for identifying unique metabolic characteristics related to the diseases, the clinical management level of gout is improved, and intervention is earlier and more accurate.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention relates to an application of a sugarcane polyphenol extract in preparation of a medicine for preventing and / or treating hyperuricemia. The invention also discloses application of the sugarcane polyphenol extract in medicines or health care products for gout caused by hyperuricemia, chronic gout, liver injury and kidney injury. The technical problem to be solved is how to provide the sugarcane polyphenol extract, the sugarcane polyphenol extract contains at least 32 polyphenol monomers, the uric acid reducing effect is improved through the synergistic effect among the polyphenol monomers, and the sugarcane polyphenol extract can be used for preparing drugs or health care products for preventing and / or treating hyperuricemia.

Described herein are crystalline forms of (3, 5-dibromo-4-hydroxyphenyl) (2-(1-hydroxyethyl) benzofuran-3-yl-4, 5, 6, 7-d4) methanone, and solvates thereof.

The invention discloses a preparation method and application of a biomarker sensor for monitoring sweat gout. According to the scheme, an Au sensing electrode is prepared on the surface of a flexible polyethylene glycol terephthalate (PET) thin film in a patterning manner by utilizing an evaporation technology, and a polypyrrole functional layer is prepared on the surface of the electrode by virtue of a molecular imprinting technology; the gout biomarker high-sensitivity detection sensor is constructed in an efficient and rapid manner; the sensor can effectively identify uric acid and xanthine in sweat and display the concentration level of the uric acid and the xanthine, and can provide real-time sensing service for prevention of gout diseases and monitoring of diagnosis and treatment processes of patients with hyperuricemia and yellow urine diseases; a scanning electron microscope is used for carrying out microtopography characterization on the molecularly imprinted functional layer, and an electrochemical workstation is used for carrying out sensing recognition performance characterization. The sensor has the characteristics of rapid identification, convenient sensing and wide detection range for biomarkers of gout, hyperuricemia and yellow urine.

The invention discloses an application of a marker combination in prediction or diagnosis of gout, the marker combination comprises an immune cell subset and clinical data, and the immune cell subset comprises virus-specific cytotoxic NK cells and inhibitory Vdelta2 cells. The marker combination comprises immune cell subgroups and clinical data, different immune cell subgroups are matched with different clinical data when a gout attack stage and a gout remission stage are distinguished, or when the gout remission stage and a healthy subject are distinguished, and high-sensitivity and high-specificity diagnosis results are achieved. Therefore, the marker combination disclosed by the invention has a wide prospect in the aspect of predicting different processes of gout, and can provide more basic research data for health management of gout high-risk people.

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.

Described herein are crystalline forms of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-d4)methanone, and solvates thereof.

Provided herein are methods for treating a disease or condition associated with one or more of: mtDNA fragmentation; cytostolic Ox-mtDNA; mtDNA release; or Casp1 activation and IL-1β production by administering an effective amount of an inhibitor of human flap endonuclease-1 (FEN1). These diseases include without limitation, an inflammatory or a neurodegenerative disease, such as Alzheimer's, disease, Parkinson's disease, atherosclerosis, NASH, asthma, inflammatory bowel disease, melanoma, metabolic pathologies, including obesity, type 2 diabetes, atherosclerosis, inflammatory bowel diseases, gout, and periodic fevers.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

The invention provides a gout recurrence prediction method, system and device and a medium. The method comprises the following steps: acquiring clinical data of gout co-disease patients during hospitalization from an electronic health recording system of a multi-center data set; processing the clinical data according to a standardization method, a minimum-maximum normalization method and a Yeo-Johnson transformation method to obtain candidate clinical features, and screening the extracted candidate clinical features by applying a plurality of feature selectors to screen out clinical features highly related to the gout co-disease recurrence risk; constructing a candidate gout recurrence prediction model for gout recurrence prediction by using a plurality of classifiers; screening the gout recurrence prediction candidate model to obtain a gout recurrence prediction model; acquiring clinical features of the patient; the gout recurrence risk of the patient is predicted according to the clinical features of the patient and the gout recurrence prediction model, the clinical features highly related to the gout co-disease recurrence risk can be accurately screened out, the efficient prediction model is constructed, and therefore reliable auxiliary decision support is provided for clinicians.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.

The present application relates to an NEK7 inhibitor, a pharmaceutical composition and a use thereof. The compound has a structural formula of formula (I). The compound of the present disclosure has good NEK7 inhibitory activity, and can be used for treating or preventing inflammatory pathological disorders (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout, etc.) regulated by the NLRP3 inflammasome.

The invention provides a preparation method and application of borneol water with high natural borneol content, and belongs to the technical field of medicines, daily chemicals and aromatherapy. The invention provides a preparation method of borneol water with high natural borneol content, and the borneol water is prepared by directly adopting fresh crushed cinnamomum camphora leaves as a borneol donor based on a two-stage vacuum steam distillation-cyclodextrin reversible carrying coupling process. According to the method, through a'two-stage vacuum steam distillation-cyclodextrin reversible carrying 'coupling process, the content of borneol in a water phase reaches 0.60 + / -0.05 g / 100mL, the chemical purity is greater than or equal to 96%, and meanwhile, long-term clarification and stability are ensured. The obtained borneol water can be effectively used for treating infant eczema, chronic kidney disease related pruritus and relieving / inhibiting pain in the acute outbreak period of gout.

The present invention relates to the field of Chinese medicinal materials, and in particular to a Chinese medicine composition, a medicine, and a preparation method and application thereof for treating hyperuricemia with hyperlipidemia. The Chinese medicine composition and medicine provided by the present invention can intervene in the treatment of asymptomatic hyperuricemia combined with hyperlipidemia, and compared with traditional uric acid-lowering drugs (febuxostat), serum uric acid can be quickly reduced, and the uric acid level can be basically controlled within a normal range. No gout symptoms are found in patients within 6 months of treatment, and complications such as hypertension, hyperglycemia, and cardiovascular and cerebrovascular diseases can be significantly reduced, and the quality of life of patients can be improved; it can also overcome the technical deficiencies of uric acid-lowering drugs, such as many adverse reactions, difficult to sustain therapeutic effects, and limited applicable populations, and has the advantages of small side effects, long-lasting efficacy, and multiple drug targets.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention belongs to the technical field of animal model analysis, and particularly relates to a modeling method of a gout damp-heat syndrome subtype model, application of a biomarker group and a detection method. According to the invention, two subtype models of pain, rheumatism and severer heat and severer heat are constructed, a UPLC-MS (Ultra Performance Liquid Chromatography-Mass Spectrometry) detection method of serum biomarkers is established, and a biomarker group comprising lauroyl carnitine, taurocholic acid, palmitoyl-L-carnitine, L-leucine, leukotriene A4, 13-Oxo-9 and 11-tridecioic acid is obtained. Researches show that the biomarker group can simply and effectively distinguish models of pain and rheumatism heavier than heat and models of heat heavier than wet and judge whether modeling of two subtypes succeeds or not, so that the biomarker group can replace conventional characterization and biochemical pathology evaluation methods, and the objectivity and operability of judgment are improved.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus reuteri JNL0037 and application thereof. The invention provides lactobacillus reuteri JNL0037, which is preserved in the China General Microbiological Culture Collection Center on December 27, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO: 33218. The lactobacillus reuteri JNL0037 can be used for preparing the lactobacillus reuteri JNL0037. The Lactobacillus reuteri JNL0037 provided by the invention has nucleoside degradation, anti-inflammatory and bacteriostatic capabilities, can be used for preparing drugs for treating hyperuricemia, gout and uric acid nephropathy, has extremely high development value and practical value, and provides a new idea for development and application of related products.